Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
1.350
-0.040 (-2.88%)
At close: Dec 5, 2025, 4:00 PM EST
1.369
+0.019 (1.42%)
After-hours: Dec 5, 2025, 7:59 PM EST
Aptevo Therapeutics Employees
Aptevo Therapeutics had 37 employees as of December 31, 2024. The number of employees decreased by 3 or -7.50% compared to the previous year.
Employees
37
Change (1Y)
-3
Growth (1Y)
-7.50%
Revenue / Employee
n/a
Profits / Employee
-$755,459
Market Cap
22.75M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
APVO News
- 25 days ago - Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors - Accesswire
- 4 weeks ago - Aptevo Therapeutics Reports 3Q25 Financial Results And Provides A Business Update - Accesswire
- 2 months ago - Aptevo Presenting Scientific and Clinical Updates at SITC and ASH, also Participating in Leading Financial and Industry Conferences in the Fourth Quarter - Accesswire
- 2 months ago - Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML - Accesswire
- 3 months ago - Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules - Accesswire
- 4 months ago - Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer - Accesswire
- 4 months ago - Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update - Accesswire
- 6 months ago - Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire